Viron Therapeutics, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Holding
- Established
- 1997-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.vironinc.com
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
Phase 1
Terminated
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Viron Therapeutics Inc
- Target Recruit Count
- 25
- Registration Number
- NCT00655395
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Serp-1 for the Treatment of Acute Coronary Syndrome
Phase 2
Terminated
- Conditions
- Unstable AnginaCoronary AtherosclerosisCoronary Restenosis
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-02-06
- Lead Sponsor
- Viron Therapeutics Inc
- Target Recruit Count
- 72
- Registration Number
- NCT00243308
- Locations
- 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Washington Hospital Center, Washington, District of Columbia, United States
© Copyright 2025. All Rights Reserved by MedPath